Related Experiment Video
Updated: Jun 12, 2026
Implantation Protocol of the Foldable Capsular Vitreous Body for Complex Vitreoretinal Surgery
Published on: April 14, 2026
Scleral thickness following fluocinolone acetonide implant (Retisert)
Mehran Taban1, Careen Y Lowder, Alexandre A C M Ventura
1Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA.
Purpose:
To evaluate whether intravitreal fluocinolone acetonide (FA) implantation (Retisert) leads to scleral thinning.
Methods:
Scleral thickness was measured at the pars plana region (4 quadrants) with anterior segment OCT (Visante) in FA implanted eyes (18) with noninfectious posterior uveitis in comparison to eyes with prior vitrectomy (8), and normal eyes without prior surgery (30).
Results:
Mean scleral thickness in normal (nonsurgical) eyes was 0.99/0.93/0.88/0.86, and 0.92 mm in the inferonasal/inferotemporal/superotemporal/superonasal quadrants, and overall, respectively. Sclera was thinner in each quadrant of the FA implanted eyes compared to the fellow or nonsurgical eyes, although none reached statistical significance, as the differences were small. However, a few FA implanted eyes demonstrated more dramatic scleral thinning than others.
Conclusions:
FA implant appears to lead to statistically nonsignificant scleral thinning overall with few exceptions. Clinicians should be aware of potential scleral thinning in select cases, important for reimplantation and long-term follow-up.
